AIM ImmunoTech CEO letter outlines Ampligen role after daraxonrasib approval
AIM ImmunoTech said Ampligen’s differentiated mechanism may support a pancreatic-cancer role following FDA approval of daraxonrasib, citing retrospective survival data and targeting DURIPANC Phase 2 readouts in 2027.